Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience

R hajjeh; L Privor-Dumm; Karen Edmond; Rosalyn O'Loughlin; Sharmila Shetty; Ulla K Griffiths; A P Bear; Adam Cohen; A Chandran; A Schuchat; Edward  (Kim) MULHOLLAND; M Santosham

doi:10.1016/j.vaccine.2010.07.028

Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience

R hajjeh, L Privor-Dumm, Karen Edmond, Rosalyn O'Loughlin, Sharmila Shetty, Ulla K Griffiths, A P Bear, Adam Cohen, A Chandran, A Schuchat, Edward (Kim) MULHOLLAND, M Santosham

Research output: Contribution to journal › Article

Abstract

The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

Original language	English
Pages (from-to)	7123-7129
Number of pages	7
Journal	Vaccine
Volume	28
Issue number	43
DOIs	https://doi.org/10.1016/j.vaccine.2010.07.028
Publication status	Published - 8 Oct 2010

Access to Document

10.1016/j.vaccine.2010.07.028

Fingerprint Dive into the research topics of 'Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience'. Together they form a unique fingerprint.

Cite this

@article{3dbcf4145e46445288e12ef6d41b21df,

title = "Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience",

abstract = "The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.",

author = "R hajjeh and L Privor-Dumm and Karen Edmond and Rosalyn O'Loughlin and Sharmila Shetty and Griffiths, {Ulla K} and Bear, {A P} and Adam Cohen and A Chandran and A Schuchat and MULHOLLAND, {Edward (Kim)} and M Santosham",

year = "2010",

month = oct,

day = "8",

doi = "10.1016/j.vaccine.2010.07.028",

language = "English",

volume = "28",

pages = "7123--7129",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "43",

}

Supporting new vaccine introduction decisions : Lessons learned from the Hib Initiative experience. / hajjeh, R; Privor-Dumm, L; Edmond, Karen; O'Loughlin, Rosalyn; Shetty, Sharmila; Griffiths, Ulla K; Bear, A P; Cohen, Adam; Chandran, A; Schuchat, A; MULHOLLAND, Edward (Kim); Santosham, M.

In: Vaccine, Vol. 28, No. 43, 08.10.2010, p. 7123-7129.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Supporting new vaccine introduction decisions

T2 - Lessons learned from the Hib Initiative experience

AU - hajjeh, R

AU - Privor-Dumm, L

AU - Edmond, Karen

AU - O'Loughlin, Rosalyn

AU - Shetty, Sharmila

AU - Griffiths, Ulla K

AU - Bear, A P

AU - Cohen, Adam

AU - Chandran, A

AU - Schuchat, A

AU - MULHOLLAND, Edward (Kim)

AU - Santosham, M

PY - 2010/10/8

Y1 - 2010/10/8

N2 - The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

AB - The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

U2 - 10.1016/j.vaccine.2010.07.028

DO - 10.1016/j.vaccine.2010.07.028

M3 - Article

VL - 28

SP - 7123

EP - 7129

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 43

ER -